Tweet
[Source: US National Library of Medicine, (LINK). Edited.]
Vaccine. 2010 Apr 16. [Epub ahead of print]
Safety and immunogenicity of prepandemic H5N1 influenza vaccines: A systematic review of the literature.
Prieto-Lara E, M?ndez AL. - Andalusian Agency for Health Technology Assessment, Emerging Technologies Observatory, Avd de la Innovaci?n s/n, Edificio Renta Sevilla, Planta 2, 41020 Seville, Spain.
A systematic review was performed to assess the safety and immunogenicity of the prepandemic H5N1 influenza vaccines licensed so far. A bibliographic search according to the COSI protocol was carried out and 8 of 235 potentially relevant publications were selected. Quality assessment was defined with both CASP and Jadad checklists. Taken together, the results from the present systematic review suggest that the inactivated split-virion formulation that includes a low antigen dose (3.8mug) and an oil-in-water emulsion-based adjuvant, represents the best option in the case of a pandemic, due to its antigen-sparing capacity and its favorable safety profile.
Copyright ? 2010 Elsevier Ltd. All rights reserved.
PMID: 20403350 [PubMed - as supplied by publisher]
-
-----
Vaccine. 2010 Apr 16. [Epub ahead of print]
Safety and immunogenicity of prepandemic H5N1 influenza vaccines: A systematic review of the literature.
Prieto-Lara E, M?ndez AL. - Andalusian Agency for Health Technology Assessment, Emerging Technologies Observatory, Avd de la Innovaci?n s/n, Edificio Renta Sevilla, Planta 2, 41020 Seville, Spain.
A systematic review was performed to assess the safety and immunogenicity of the prepandemic H5N1 influenza vaccines licensed so far. A bibliographic search according to the COSI protocol was carried out and 8 of 235 potentially relevant publications were selected. Quality assessment was defined with both CASP and Jadad checklists. Taken together, the results from the present systematic review suggest that the inactivated split-virion formulation that includes a low antigen dose (3.8mug) and an oil-in-water emulsion-based adjuvant, represents the best option in the case of a pandemic, due to its antigen-sparing capacity and its favorable safety profile.
Copyright ? 2010 Elsevier Ltd. All rights reserved.
PMID: 20403350 [PubMed - as supplied by publisher]
-
-----